Shanghai and Shenzhen A Shrs Midday Down 0.4% to 2.3%; Banks and Pharma Stocks Buck TrendAASTOCKS News·Jun 22 at 11:10 PM399001+2.21%000001+0.72%
The A-shares opened lower and rose higher, with all three major indices turning positive. The chemical and electric grid sectors collectively surged, the Hang Seng Index fell over 1%, tech stocks continued to decline, and Shanghai silver dropped over 13%Wallstreetcn·Feb 6 at 02:24 AM000554-1.09%301111+5.54%
February 6th Midday Review: ChiNext opened lower but rose to gain 0.65%, with chemical and robotics concept stocks collectively strengtheningWallstreetcn·Feb 5 at 09:30 PM399006+3.06%002728+2.44%
Chinese medicine stocks opened sharply higher, with Panlong Pharmaceutical and TY PHAR. hitting the daily limit, and Bio Valley and LSPG rising over 10%Wallstreetcn·Feb 5 at 07:27 PM301111+5.54%002864+2.17%
The three major A-share indices of Shanghai and Shenzhen opened lower by 0.9% to 1.2%, with oil and gold stocks weak, while traditional Chinese medicine stocks rose against the trendAASTOCKS·Feb 5 at 07:26 PM600938-0.89%600489+5.07%
TY PHAR. released its performance for the first three quarters, with a net profit attributable to the parent company of 65.2171 million yuan, a year-on-year increase of 985.18%Zhitong·Oct 23, 2025 at 04:54 AM002728+2.44%
The influenza sector has risen again, with CISEN and TY PHAR. both hitting the daily limitZhitong·Oct 21, 2025 at 09:49 PM603367+1.73%002728+2.44%
TY PHAR. released its performance for the first half of the year, with a net profit attributable to the parent company of 38.077 million yuan, an increase of 1313.23%Zhitong·Aug 21, 2025 at 06:28 AM002728+2.44%
TY PHAR. : The acetaminophen tablets produced and sold by the company can be used for symptoms related to Chikungunya feverZhitong·Aug 8, 2025 at 02:45 AM002728+2.44%
The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%Zhitong·Aug 5, 2025 at 08:52 PM002275+0.15%300199+4.46%
TY PHAR. released its first-quarter performance, with a net profit attributable to the parent company of 31.5673 million yuan, a year-on-year increase of 244.82%Zhitong·Apr 25, 2025 at 09:49 AM002728+2.44%
TY PHAR. has repurchased 2.48% of its shares, costing 93.9418 million yuanZhitong·Mar 3, 2025 at 02:56 AM002728+2.44%
TY PHAR. : Doxycycline hydrochloride tablets pass consistency evaluationZhitong·Feb 27, 2025 at 01:41 AM002728+2.44%
